B
ELEV

Bailard’s Elevation Oncology ELEV Stock Holding History

Bailard’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23,500
Closed -$59K – 716
2022
Q1 		$59K Buy
+23,500
New +$94.2K ﹤0.01% 708

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Bailard's ELEV Position: Q2 2022 in Review

Bailard sold out of Elevation Oncology (ELEV) in Q2 2022, closing a stake of 23,500 shares — an estimated $59K sold.

Bailard first reported a position in ELEV in Q1 2022 and held it in 1 quarter. The position peaked at $59K in Q1 2022. 27 funds tracked by Wall St. Rank hold ELEV as of Q2 2022.

  • Bailard reported no remaining Elevation Oncology position as of Q2 2022 after selling out during the quarter.
  • Bailard sold 23,500 Elevation Oncology shares in Q2 2022, an estimated $59K.
  • Bailard first reported a position in Elevation Oncology in Q1 2022 and held it in 1 quarter.
  • Bailard's Elevation Oncology position peaked at $59K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.